The past few weeks have seen leading IP firms make a series of high-profile appointments.
At Mewburn Ellis, Adam Gregory, part of the firm’s industry-leading life sciences patent team, has been promoted to partner. This promotion sees the Mewburn Ellis partnership expand to 44.
Based in Bristol, Adam has been with Mewburn Ellis since 2012 and has built a strong practice specializing in portfolios relating to therapeutics (particularly immunotherapies, including adoptive cellular therapies), antibody technology, diagnostics, and regenerative medicine for his European, US, and Singaporean clients.
In addition, June Lyons (Manchester), Susie Harrison (Cambridge) and Rachel Jones (Bristol) have been appointed to the role of Patent Director, while Ed Harrison (Bristol) has been appointed to the role of Trademark Director.
With the firm since 1990, June Lyons is an experienced member of the firm’s highly regarded chemistry practice, as are Susie Harrison and Rachel Jones in the life sciences team. Ed Harrison sits within the firm’s rapidly expanding trademark group, working closely alongside former CITMA chair Kate O’Rourke, who joined the firm in 2019 to lead the firm’s trademark services.
Mewburn Ellis Managing Partner Richard Clegg commented:
“These appointments send a very strong message to the market around this firm’s clear and continued growth trajectory and ability to attract and develop the leading talent in European IP. We have ambitious plans for further growth over the coming 18 months across all our key service offerings, not least in our European trademark practice and Munich office. We’re delighted to announce these appointments and congratulate each colleague on their well-deserved new roles”.
Over at EIP, meanwhile, life sciences specialist Monika Rai has been appointed to further enhance EIP’s life sciences capabilities. Joining the EIP partnership from Mathys & Squire LLP, Monika’s professional experience spans over fifteen years and includes private practice as well as in-house experience with GSK. She has significant experience in opposition proceedings at the EPO, often involving multiple parties. Her expertise in the pharmaceutical sector includes representing innovators in the fields of cancer immunotherapy, microbiome therapeutics, gene therapy, nucleotide and peptide vaccines, antibodies, RNAi and diagnostics.
Commenting on her appointment, Monika said:
“EIP’s reputation as a modern and agile firm and its representation of clients at the highest levels in ground-breaking areas of patent law is attractive to clients and attorneys alike. I have been impressed by the experience and ethos of the team at EIP and am looking forward to helping develop the firm’s life sciences practice. I am really excited about our life sciences offering combining top-notch contentious and strategic pharma experience with expertise in areas such as artificial intelligence which are of immense interest to this sector.”
Heather McCann, partner at EIP, said:
“Monika is a very well-respected IP practitioner, and her appointment is a significant addition to EIP’s capabilities in the life sciences sector. Together with partner Gareth Probert, who joined the Life Tech team in February 2020, we are looking forward to Monika playing a key role in the development of the practice.”
Finally, Dallas-based Thompson & Knight have announced that three leading intellectual property trial lawyers – Phillip Philbin, Jamie McDole and Michael Karson – have joined the Firm as Partners. With a combined 60 years of legal expertise, including experience involving some of the highest-profile companies in the US, and a proven ability to deliver successful outcomes for clients seeking to protect high-value IP assets, Phillip, Jamie and Michael will complement Thompson & Knight’s broader litigation group.
“Phillip, Jamie, and Michael significantly broaden and deepen an already robust IP defense practice at Thompson & Knight and add increased firepower to our plaintiff-side patent infringement capabilities. The addition of this team is a natural complement to our broader litigation group and will be beneficial to the Firm and our clients as we continue to grow in a variety of practice areas in Texas,” said Managing Partner Mark M. Sloan.